Was Jim Cramer Right About Moderna (MRNA) Stock?

Back in 2024, on May 14, Mad Money’s Jim Cramer was asked about Moderna, Inc. (NASDAQ:MRNA), explaining that some family members had owned it during its run-up to $400 and that he was now considering buying it around $130. Cramer confirmed his long-standing belief in the stock back then, saying:

“I’m a believer. I’ve been a believer with Steph Bancel since $16. I’ve never backed away, other than the fact it went crazy during COVID and then it crashed. And ever since it crashed, I’m in. I’m in.”

Cramer’s confidence in Moderna proved costly, as the stock plunged 81.28% over the past year.

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company specializing in mRNA-based vaccines and therapies, best known for its COVID-19 vaccine. Earlier in March, Cramer gave a reason for the stock’s recent dip, saying:

“Now, let’s consider the other side of the trade, the biggest losers, all of which were somehow connected to the data center except Moderna, which plunged 7% because of Financial Time’s story. It says they might… be targeted by RFK Junior at Health and Human Services and it’s certainly possible.”

Addressing the company’s struggles, Cramer said the following in April:

“[On MRNA being down after an FDA official resigning] I found that this was really extraordinary. Dedicated official. Obviously gonna be fired or has to leave. Has favored MRNA. MRNA had been part of the discourse to be able to . . .personalized cancer vaccines. If that’s halted. Then I think that you would question the worth of Moderna. David, Moderna… problematic. Problematic…”

While we acknowledge the potential of MRNA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than MRNA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None.